National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 19 of 41
Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women
NCT00592124
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
NCT00466817
Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)
NCT00611702
Intensive Viral Dynamics Substudy of A5248
NCT00852618
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
NCT00660972
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
NCT00646152
Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults
NCT00546585
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
NCT00537147
Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine
NCT00641017
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
NCT00604175
H9 Priming Study in Healthy Adults
NCT00617331
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
NCT00618605
Enteroaggregative E.Coli (EAEC)
NCT00362869
Etanercept for the Treatment of Lupus Nephritis
NCT00447265
Ebola and Marburg Virus Vaccines
NCT00605514
Dyskinesia, Heterotaxy and Congenital Heart Disease
NCT00608556
Influenza in People With Normal and Weakened Immune Systems
NCT00533182
HIV Screening in the Emergency Department Setting
NCT00667186
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
NCT00537394
MRI to Measure Liver Fat Content
NCT00594412
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
NCT00580606
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
NCT00614731
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
NCT00302952
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
NCT00515827
Live Lung Donor Retrospective Study
NCT00553397
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
NCT00528489
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
NCT00485264
Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care
NCT00678600
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
NCT00516035
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
NCT00531921
Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome
NCT00527878
Collection of Samples and Data for the National Marrow Donor Program Repository
NCT00495300
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
NCT00393276
Live Kidney Donor Study
NCT00608283
Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
NCT00472719
Proleukin and Rapamune in Type 1 Diabetes
NCT00525889
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
NCT00515099
Malaria Incidence in Infants in Bancoumana, Mali
NCT00508417
Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
NCT00486408
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
NCT00489931
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
NCT00489385
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
NCT00459316
Pneumococcal Reference Standard
NCT00479323
Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients
NCT00466804
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
NCT00458393
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
NCT00488046
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
NCT00490100
Phase 1 Safety Study of Two Experimental HIV Vaccines
NCT00479999
Pilot Study of Genotypic Analysis
NCT00421837
Oral Immunotherapy for Childhood Egg Allergy
NCT00461097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.